Astellas and Vir Biotechnology Forge $1.7 Billion Collaboration for Prostate Cancer Treatment

Astellas Pharma and Vir Biotechnology have entered into a significant $1.7 billion global collaboration aimed at advancing Vir's PSMA-targeted bispecific T-cell engager (TCE), VIR-5500, for the treatment of prostate cancer. This partnership, led by Vir's CEO Marianne De Backer, Ph.D., includes an upfront payment of $335 million, which comprises $240 million in cash, a $75 million equity investment, and a $20 million milestone payment. The collaboration is particularly timely as Astellas seeks to strengthen its position in the prostate cancer market amid the impending patent expiration of its existing drug, Xtandi (enzalutamide).

Fierce Biotech

VIR-5500 utilizes Vir's proprietary PRO-XTEN dual-masking technology, designed to keep the therapy inactive until it reaches the tumor site. This innovative approach aims to enhance the therapeutic index while minimizing side effects associated with T-cell activation, such as cytokine release syndrome (CRS). Initial phase 1 data presented at the upcoming 2026 ASCO Genitourinary Cancers Symposium (ASCO GU) indicates promising efficacy, with 82% of heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients achieving a 50% or greater reduction in PSA levels.

Fierce Biotech

The collaboration occurs in a competitive landscape where other companies, such as Novartis with its radioligand therapy Pluvicto and Janux Therapeutics with its TCE candidate JANX007, are also advancing prostate cancer treatments. Despite these advancements, there remains a significant unmet medical need, as only about 30% of mCRPC patients survive five years post-diagnosis. The dual-masking technology of VIR-5500 is positioned to offer a differentiated treatment option compared to existing therapies.

Fierce Biotech

De Backer emphasized Astellas' expertise in prostate cancer, stating, “Astellas emerged as the perfect partner... with very deep expertise internally on clinical development.” She highlighted the potential of the partnership to broaden the patient populations eligible for VIR-5500. Anthony Jarkowski, Astellas' primary focus lead of immuno-oncology, noted the promising efficacy and manageable safety profile of VIR-5500, reinforcing the rationale behind the collaboration.

Fierce Biotech

While the partnership is seen as a strategic move, some industry observers may question the long-term viability of TCEs given the inherent toxicity risks associated with immune activation. The presence of CRS in 50% of patients during trials raises concerns about the safety profile, despite the majority of cases being classified as grade 1.

Fierce Biotech

Vir Biotechnology plans to advance VIR-5500 into phase 3 testing by 2027, with ongoing dose-expansion cohorts in metastatic hormone-sensitive prostate cancer expected to begin in the second quarter of 2026. The collaboration with Astellas will also involve shared development costs, with Astellas taking responsibility for commercialization outside the U.S.

Fierce Biotech

• “It’s the promise of what T-cell engagers can deliver,” — Anthony Jarkowski, Primary Focus Lead of Immuno-Oncology, Astellas

Fierce Biotech

• “It is remarkable to see these early signs of profound anti-tumor activity in heavily pretreated mCRPC patients, and the favorable tolerability with minimal CRS to date means VIR-5500 could play a role in treating earlier disease,” — Johann de Bono, Principal Investigator, The Institute of Cancer Research, U.K.

Fierce Biotech